November 6, 2024

Sarepta Announces Discontinuation of SRP-5051 Development for Duchenne

Sarepta Therapeutics today announced that the company is discontinuing its SRP-5051 (vesleteplirsen) development program, including the global, Phase 2, multi-arm, ascending dose MOMENTUM study. Vesleteplirsen is an investigational, next-generation treatment utilizing Sarepta’s PPMO chemistry and…

Learn More

March 19, 2024

WATCH: Sarepta Therapeutics – Data update from MOMENTUM study, SRP-5051 (Webinar Recording)

Sarepta Therapeutics recently joined PPMD for a community webinar: Data Update From the MOMENTUM Study of SRP-5051. Sarepta Therapeutics was invited to share data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051…

Learn More

January 29, 2024

Sarepta Therapeutics Reports Positive Data from Part B of MOMENTUM Study of SRP-5051

Sarepta Therapeutics, Inc. today announced positive data from Part B of SRP-5051-201, the MOMENTUM study. MOMENTUM is a global, Phase 2, multi-ascending dose clinical trial of SRP-5051 that enrolled patients aged 8 to 21 years….

Learn More

September 6, 2022

Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051

Sarepta Therapeutics has announced that the FDA has lifted the clinical hold on SRP-5051 (vesleteplirsen) following a serious adverse event of hypomagnesemia (low magnesium). SRP-5051 is Sarepta’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat…

Learn More

June 23, 2022

Sarepta Therapeutics Announces Clinical Hold on Study SRP-5051-201 (MOMENTUM)

This afternoon Sarepta Therapeutics, Inc. announced that the FDA has placed a clinical hold on SRP-5051 (vesleteplirsen) following a serious adverse event of hypomagnesemia (low magnesium). SRP-5051 is Sarepta’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)…

Learn More

January 5, 2022

Sarepta Therapeutics Shares MOMENTUM, Study SRP-5051-201, Update

Sarepta Therapeutics has shared an update that SRP-5051-201, the MOMENTUM study (NCT04004065), is now recruiting Part B. MOMENTUM is a Phase 2, two-part, multiple-ascending-dose study of SRP-5051 for dose determination, then dose expansion, in patients…

Learn More

November 8, 2021

Recap: Recent Research Updates

Welcome to FALL Time flies! Over the past few months, we have seen a number of announcements regarding drug development, changes to clinical trials, and new trials opening or on the horizon. For many, it…

Learn More

September 27, 2021

Sarepta Therapeutics Plans to Initiate Part B of the MOMENTUM Study of SRP-5051 in Patients with Duchenne Following Positive Interactions with FDA

PPMD is pleased to share that Sarepta Therapeutics plans to initiate Part B of the MOMENTUM study of SRP-5051 in patients with Duchenne muscular dystrophy following positive interactions with the U.S. Food and Drug Administration…

Learn More

May 3, 2021

Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051

Sarepta has announced positive results from Part A of the MOMENTUM study (Study 5051-201), a Phase 2 clinical trial of SRP-5051, its next-generation treatment for individuals with Duchenne who are amenable to exon 51 skipping. Part…

Learn More

December 7, 2020

Sarepta Announces Positive Clinical Results from MOMENTUM Phase 2 Clinical Trial of SRP-5051

Sarepta has announced positive results from the ongoing MOMENTUM study of SRP-5051, its next-generation treatment for individuals with Duchenne who are amenable to exon 51 skipping. This is the first clinical data from SRP-5051, an…

Learn More